Latest News & Updates
The treatment of patients with multiple myeloma is poised to undergo a dramatic transformation, as novel monoclonal antibodies and combination strategies race toward approval.
Entrepreneur James Feldman, chief innovation officer of the Chicago-based company Shift Happens!, calls himself “a doctor for business.”
The FDA has extended the review period for panobinostat (LBH589) in combination with bortezomib (Velcade) and dexamethasone for patients with previously treated multiple myeloma by 3 months, placing a new decision date in early 2015.
Urologists hear quite a bit about risk from the legislative and regulatory angles.
Pfizer and Merck KGaA have agreed to collaborate on the development of the PD-L1 inhibitor MSB0010718C as a potential treatment for multiple types of cancer.
Latest Peer Exchange Discussions
Nicholas J. Vogelzang, MD, discusses the rapidly evolving treatment paradigm for patients with renal cell carcinoma, which exploded in the early 2000's with the introduction of TKIs and mTOR inhibitors and is set to undergo a second sea change with the immune checkpoint inhibitors. View Now
Moderator Robert A. Figlin, MD, and panelists Brian I. Rini, MD, FACP, Daniel Heng, MD, MPH, Janice P. Dutcher, MD, Charles A. Henderson, MD, describe the changing treatment landscape for renal cell carcinoma in the final segment of the discussion. View Now
Primo N. Lara, Jr, MD, discusses the role of histology in guiding the treatment of individuals with NSCLC in this segment. View Now
Most Popular Right Now
Online CME Activities